PAS
BCRX icon

Point72 Asia (Singapore)’s BioCryst Pharmaceuticals BCRX Stock Holding History

Point72 Asia (Singapore)’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-72,666
Closed -$449K – 980
2024
Q2 		$449K Buy
+72,666
New +$401K 0.09% 166

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

Point72 Asia (Singapore)'s BCRX Position: Q3 2024 in Review

Point72 Asia (Singapore) sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2024, closing a stake of 72,666 shares — an estimated $449K sold.

Point72 Asia (Singapore) first reported a position in BCRX in Q2 2024 and held it in 1 quarter. The position peaked at $449K in Q2 2024. 257 funds tracked by Wall St. Rank hold BCRX as of Q3 2024.

  • Point72 Asia (Singapore) reported no remaining BioCryst Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Point72 Asia (Singapore) sold 72,666 BioCryst Pharmaceuticals shares in Q3 2024, an estimated $449K.
  • Point72 Asia (Singapore) first reported a position in BioCryst Pharmaceuticals in Q2 2024 and held it in 1 quarter.
  • Point72 Asia (Singapore)'s BioCryst Pharmaceuticals position peaked at $449K in Q2 2024.
  • 257 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2024.

Based on Point72 Asia (Singapore)'s 13F filing for Q3 2024, filed 14 Nov 2024.